Fire at Serum Institute building in Pune; vaccine output not hit: Report

SII is manufacturing a vaccine developed by Oxford University and US drugmaker AstraZeneca

fire incident
The incident of fire at the Serum Institute of India took place at Manjari Plant. | Photo: @ANI
Reuters
2 min read Last Updated : Jan 21 2021 | 5:40 PM IST
A big fire broke out on Thursday inside the sprawling complex of the Serum Institute of India (SII), the world’s biggest vaccine maker, but a source close to the firm said current production of coronavirus vaccines was unaffected.

Videos and pictures from Reuters partner ANI showed black smoke billowing out of a grey building in SII’s massive headquarters complex spread over tens of acres in the western city of Pune. 

“Thank you everyone for your concern and prayers,” SII CEO Adar Poonawalla said on Twitter.

“So far the most important thing is that there have been no lives lost or major injuries due to the fire, despite a few floors being destroyed.”

SII is producing around 50 million doses of a vaccine developed by Oxford University and AstraZeneca a month at other facilities in the complex.

The fire department said at least five fire trucks had been sent to fight the blaze at the building, which the source described as an “under-construction vaccine plant”.

There was no immediate word on the cause of the fire.

Many low- and middle-income countries are depending on SII delivering vaccines to fight the epidemic.

The AstraZeneca vaccine is already in use in India and has also been shipped to countries such as Bangladesh, Nepal, the Maldives and Bhutan.

The company is also getting ready to produce a vaccine being developed by the U.S. company Novavax Inc.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusSerum Institute of IndiaCoronavirus Vaccine

Next Story